Gelon September 20th 丨 Megascience Vision-B (06622.HK) announced in a statement that the anti-glaucoma drug Bimie Frontline Plus eye drops (Crystal Beiquing) developed and produced by the company has been approved for listing by the State Drug Administration ("State Drug Administration").
According to the disclosure, Bimie Frontline Plus eye drops (Crystal Beiquing) is China's first preservative-free single-dose Bimie Frontline Plus eye drops, used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. This medication is preservative-free, avoiding damage to the ocular surface caused by long-term use of preservative-containing drugs in patients with glaucoma. At the same time, this medication also helps improve patients' comfort during treatment and reduces the risk of preservative-related sensitivity. Its once-daily dosing frequency also helps improve patient compliance.
